Djordjevic, F.; Ljujic, K.; Stanic, N.; Nikolic, N.; Markovic, I.; Spasic, J.
Evaluating the Predictive Value of Clinical Factors for Pembrolizumab Efficacy and Safety in Advanced NSCLC with High PD-L1 Expression (TPS ≥ 50%). J. Clin. Med. 2025, 14, 6200.
https://doi.org/10.3390/jcm14176200
AMA Style
Djordjevic F, Ljujic K, Stanic N, Nikolic N, Markovic I, Spasic J.
Evaluating the Predictive Value of Clinical Factors for Pembrolizumab Efficacy and Safety in Advanced NSCLC with High PD-L1 Expression (TPS ≥ 50%). Journal of Clinical Medicine. 2025; 14(17):6200.
https://doi.org/10.3390/jcm14176200
Chicago/Turabian Style
Djordjevic, Fedja, Katarina Ljujic, Nemanja Stanic, Neda Nikolic, Ivan Markovic, and Jelena Spasic.
2025. "Evaluating the Predictive Value of Clinical Factors for Pembrolizumab Efficacy and Safety in Advanced NSCLC with High PD-L1 Expression (TPS ≥ 50%)" Journal of Clinical Medicine 14, no. 17: 6200.
https://doi.org/10.3390/jcm14176200
APA Style
Djordjevic, F., Ljujic, K., Stanic, N., Nikolic, N., Markovic, I., & Spasic, J.
(2025). Evaluating the Predictive Value of Clinical Factors for Pembrolizumab Efficacy and Safety in Advanced NSCLC with High PD-L1 Expression (TPS ≥ 50%). Journal of Clinical Medicine, 14(17), 6200.
https://doi.org/10.3390/jcm14176200